When: Harvest premium while defining downside

Then: Cash-secured puts at $80 strike

HOLD with preemptive trim and raised stop discipline; avoid adding until confirmation above $98-$101.50

• Goodwill impairment of $5.7 billion in Q3 last year artificially suppressed trailing EPS, distorting forward P/E and PEG ratios (P/E of 11, PEG of 0.25)
• 200-day moving average at $84.81 is untested structural support, not a proven bounce level with buyer precedent
• Current price at $94 sits below 50-day MA at $101 and Bollinger middle at $98; ATR of $2.50 implies $5 weekly range suggesting potential test of $87.60
• Q2 EPS jump at CVS happened before back-half weighted seasonal peak for medical cost utilization; UnitedHealth commercial book under pressure indicates sector-wide canary
• Glenview exit removes known activist pressure point that had been enforcing operational discipline for two years
• JPMorgan AI hire is a 5-year aspirational signal with no immediate execution multiple; Robbins departure is a near-term negative
• RSI sub-40 sustained for three weeks is signature of sustained distribution, not oversold base setup for mean reversion
• MACD histogram contracting is necessary but not sufficient condition for a bottom; Bollinger lower band break often extends trend rather than reversing it
• Negative tangible book value, $76 billion in debt, and unresolved segment-level risks create fat left tail in return distribution
• Dividend yield of 2.86% insufficient compensation for risk profile during regime change
• Analyst target upside of 15-22% versus 10% downside assumes consensus path; negative tangible book stocks trade in much wider distribution
• If CVS gaps below $80 on bad medical cost trend print, $84 becomes a midpoint not a floor

→ vs aggressive: Forward P/E of 11 and PEG of 0.25 are not genuine undervaluation; the cheap multiple reflects artificially suppressed trailing EPS from a $5.7 billion goodwill impairment wash-out, not organic business quality

→ vs aggressive: Q2 forty percent EPS jump at CVS does not refute medical cost trend concern; utilization patterns are back-half weighted and Q2 preceded the real seasonal stress test

→ vs aggressive: UnitedHealth commercial book pressure is not sector contagion already refuted by CVS; UnitedHealth is the canary and CVS is the next cage to be tested

→ vs aggressive: 200-day moving average at $84.81 is an untested reference line, not support with a track record of holding; calling it structural support is unsupported by data

→ vs aggressive: RSI bounce from 28 to 38 and MACD contraction indicate decelerating selling pressure, a necessary but not sufficient condition for a bottom; reading oversold as automatic reversal is a classic mistake

→ vs aggressive: Sub-40 RSI sustained for three weeks is not a setup for mean reversion to upside; it is the signature of sustained distribution that often continues rather than reverses

→ vs aggressive: Bollinger lower band break is momentum extension that often resolves by continuing the trend, not a buy signal as characterized

→ vs aggressive: Glenview exit removes activist advocate for operational discipline; aspirational JPMorgan AI hire does not compensate for lost internal pressure point on near-term execution

→ vs aggressive: Asymmetry math (10% downside to $84 versus 15-22% upside) treats analyst targets as serious base rates; negative tangible book and elevated leverage create wider distribution with fat left tail that breaks the math

→ vs aggressive: Original trim recommendation of 50-75% after close below $84 is too lenient given technical setup; preemptive trim of 15-25% at current levels is appropriate for a name with negative tangible book and broken short-term trend

→ vs aggressive: Cash-secured puts at $80 strike should be sized small because testing that level indicates structural break, not buying opportunity as framed

HOLD current position with cash-secured puts at $80 strike as primary risk management tool; add on reclaim of 50 SMA at $101.50 with volume above 10M shares; trim 50-75% on weekly close below $84

• Forward P/E of 11.06 and deleveraging from $57B to $50B in six months are legitimate fundamental positives that cannot be dismissed
• Q2 Health Care Benefits segment up 40% and raised AOI guidance represent confirmed catalysts that have already moved through the tape
• 200 SMA at $84 is a rising moving average that has NOT been tested or confirmed as support; calling it structural support is intellectually lazy
• Stock remains 11% above the 200 SMA; long-term trend is intact and does not justify preemptive trimming
• Cash-secured puts at $80 strike is the balanced risk management tool: generates income, defines risk below current price, positions to add at 15% discount
• Sub-40 RSI sustained for three weeks indicates regime change, not mean reversion; MACD contraction is necessary but not sufficient for a base
• Gap between current price and 50 SMA at $101.50 is significant resistance requiring confirmation to clear on volume above 10M shares
• Q2 cash flow of $5.65 billion in a single quarter and 2.86% dividend yield are real value metrics not to be dismissed
• Medical cost trend risk is heavily back-half weighted and Q3/Q4 reporting is the real test of the utilization concern
• Glenview exit and governance changes are multi-year process variables that will not move the stock in the next 90 days
• Neither aggressive (momentum chase) nor conservative (capitulation) approach respects the actual risk asymmetry in front of the trader

→ vs aggressive: 200 SMA at $84 is untested rising MA, not confirmed structural floor; treating it as a floor that has held multiple times is wrong and creates fat left tail risk of 30-40% drawdown if it fails on first real test

→ vs aggressive: Medical cost trend risk dismissed too casually; CVS Q2 beat clears a low bar but utilization is back-half weighted and Q3/Q4 reporting is the real test

→ vs conservative: Preemptive 15-25% trim unjustified; stock still 11% above 200 SMA and long-term trend intact; conflating short-term technical drawdown with a broken name

→ vs conservative: Too dismissive of valuation: forward P/E 11 is not nothing, Q2 cash flow $5.65B is real, 2.86% yield is real; cannot dismiss all metrics because trailing earnings are artificially impaired

→ vs conservative: Overweighting governance signals; board refresh and Glenview exit play out over years not weeks and neither will move the stock in the next 90 days